Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring

NCT01730339 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01730339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01730339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
October 31, 2014
Enrollment
103 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

reduction of hypertrophic skin scarring